$35.41
1.86% today
Nasdaq, Sep 08, 04:19 pm CET
ISIN
US52490G1022
Symbol
LEGN

Legend Biotech Corp - ADR Target price 2025 - Analyst rating & recommendation

Legend Biotech Corp - ADR Classifications & Recommendation:

Buy
92%
Hold
8%

Legend Biotech Corp - ADR Price Target

Target Price $77.52
Price $36.08
Potential
Number of Estimates 22
22 Analysts have issued a price target Legend Biotech Corp - ADR 2026 . The average Legend Biotech Corp - ADR target price is $77.52. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 26 analysts: 24 Analysts recommend Legend Biotech Corp - ADR to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Legend Biotech Corp - ADR stock has an average upside potential 2026 of . Most analysts recommend the Legend Biotech Corp - ADR stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 627.24 1,071.00
119.98% 70.75%
EBITDA Margin -44.93% -11.64%
74.76% 74.09%
Net Margin -28.22% -30.21%
84.47% 7.04%

22 Analysts have issued a sales forecast Legend Biotech Corp - ADR 2025 . The average Legend Biotech Corp - ADR sales estimate is

$1.1b
Unlock
. This is
34.41% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.2b 49.72%
Unlock
, the lowest is
$970m 21.77%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $627m 119.98%
2025
$1.1b 70.75%
Unlock
2026
$1.6b 52.47%
Unlock
2027
$2.2b 35.82%
Unlock
2028
$2.6b 15.37%
Unlock
2029
$3.0b 15.79%
Unlock
2030
$3.4b 13.47%
Unlock
2031
$3.8b 11.72%
Unlock
2032
$4.1b 8.09%
Unlock

12 Analysts have issued an Legend Biotech Corp - ADR EBITDA forecast 2025. The average Legend Biotech Corp - ADR EBITDA estimate is

$-125m
Unlock
. This is
35.93% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-74.6m 61.67%
Unlock
, the lowest is
$-178m 8.31%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-282m 44.48%
2025
$-125m 55.77%
Unlock
2026
$230m 284.85%
Unlock
2027
$662m 187.37%
Unlock
2028
$600m 9.42%
Unlock
2029
$819m 36.64%
Unlock
2030
$1.1b 39.11%
Unlock
2031
$1.3b 11.14%
Unlock
2032
$1.4b 7.89%
Unlock

EBITDA Margin

2024 -44.93% 74.76%
2025
-11.64% 74.09%
Unlock
2026
14.11% 221.22%
Unlock
2027
29.85% 111.55%
Unlock
2028
23.44% 21.47%
Unlock
2029
27.66% 18.00%
Unlock

20 Legend Biotech Corp - ADR Analysts have issued a net profit forecast 2025. The average Legend Biotech Corp - ADR net profit estimate is

$-324m
Unlock
. This is
0.54% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-105m 67.83%
Unlock
, the lowest is
$-611m 87.92%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-177m 65.84%
2025
$-324m 82.78%
Unlock
2026
$226m 169.91%
Unlock
2027
$367m 62.29%
Unlock
2028
$831m 126.23%
Unlock
2029
$1.0b 23.70%
Unlock
2030
$1.3b 23.87%
Unlock
2031
$1.4b 8.58%
Unlock
2032
$1.4b 3.81%
Unlock

Net Margin

2024 -28.22% 84.47%
2025
-30.21% 7.04%
Unlock
2026
13.85% 145.85%
Unlock
2027
16.55% 19.49%
Unlock
2028
32.46% 96.13%
Unlock
2029
34.67% 6.81%
Unlock
2030
37.85% 9.17%
Unlock
2031
36.79% 2.80%
Unlock
2032
35.33% 3.97%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.48 -0.88
67.35% 83.33%
P/E negative
EV/Sales 5.49

20 Analysts have issued a Legend Biotech Corp - ADR forecast for earnings per share. The average Legend Biotech Corp - ADR EPS is

$-0.88
Unlock
. This is
1.12% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.28 68.54%
Unlock
, the lowest is
$-1.66 86.52%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.48 67.35%
2025
$-0.88 83.33%
Unlock
2026
$0.61 169.32%
Unlock
2027
$0.99 62.30%
Unlock
2028
$2.25 127.27%
Unlock
2029
$2.78 23.56%
Unlock
2030
$3.45 24.10%
Unlock
2031
$3.74 8.41%
Unlock
2032
$3.89 4.01%
Unlock

P/E ratio

Current -40.54 45.06%
2025
-41.16 1.53%
Unlock
2026
58.88 243.05%
Unlock
2027
36.28 38.38%
Unlock
2028
16.04 55.79%
Unlock
2029
12.96 19.20%
Unlock
2030
10.47 19.21%
Unlock
2031
9.64 7.93%
Unlock
2032
9.28 3.73%
Unlock

Based on analysts' sales estimates for 2025, the Legend Biotech Corp - ADR stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 7.38 64.91%
2025
5.49 25.63%
Unlock
2026
3.60 34.41%
Unlock
2027
2.65 26.38%
Unlock
2028
2.30 13.32%
Unlock
2029
1.98 13.64%
Unlock
2030
1.75 11.87%
Unlock
2031
1.57 10.49%
Unlock
2032
1.45 7.49%
Unlock

P/S ratio

Current 8.10 64.94%
2025
6.03 25.60%
Unlock
2026
3.95 34.41%
Unlock
2027
2.91 26.38%
Unlock
2028
2.52 13.33%
Unlock
2029
2.18 13.63%
Unlock
2030
1.92 11.87%
Unlock
2031
1.72 10.49%
Unlock
2032
1.59 7.49%
Unlock

Current Legend Biotech Corp - ADR Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JP Morgan
Locked
Locked
Locked Aug 25 2025
RBC Capital
Locked
Locked
Locked Aug 12 2025
Morgan Stanley
Locked
Locked
Locked Aug 12 2025
HC Wainwright & Co.
Locked
Locked
Locked Jul 17 2025
Morgan Stanley
Locked
Locked
Locked Jul 10 2025
HC Wainwright & Co.
Locked
Locked
Locked Jul 08 2025
UBS
Locked
Locked
Locked Jul 02 2025
Analyst Rating Date
Locked
JP Morgan:
Locked
Locked
Aug 25 2025
Locked
RBC Capital:
Locked
Locked
Aug 12 2025
Locked
Morgan Stanley:
Locked
Locked
Aug 12 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jul 17 2025
Locked
Morgan Stanley:
Locked
Locked
Jul 10 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jul 08 2025
Locked
UBS:
Locked
Locked
Jul 02 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today